While TCRs have demonstrated only anecdotal evidence and a slow developmental pace [10], CAR usage has culminated into six FDA approvals for T cell-based therapies—idecabtagene vicleucel and ciltacabtagene autoleucel targeting B cell maturation antigen (BCMA) in multiple myeloma, and lisocabtagene maraleucel, tisagenlecleucel, brexucabtagene autoleucel, and axicabtagene ciloleucel targeting CD19 in a variety of B-cell lymphomas and leukemias [11]. Here, TNFRSF17 is linked to B-cell non-Hodgkin lymphoma.